Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Exploring the TED treatment landscape with an ophthalmologist focusing on Horizon's Tepezza (teprotumumab-trbw), Immunovant's Batoclimab (IMVT-1401), and Viridian's VRDN-001.

Ticker(s): HZNP, VRDN, IMVT

Who's the expert?

Institution: ASCENTION

Oculoplastic Surgeon at Ascention in Austin, TX; previously Professor of Ophthalmology at Baylor College of Medicine
Manages ~120 chronic TED patients
Clinical and research interests in ophthalmology and oculoplastic surgery, having 20 years of experience and over 120 peer-reviewed publications.

Interview Goal

On this call we will be digging in to the treatment options currently in use and in development for Thyroid Eye Disease (TED) including Horizon's Tepezza (teprotumumab-trbw), Immunovant's Batoclimab (IMVT-1401), and Viridian's VRDN-001.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.